Ipilimumab granulomatous interstitial nephritis

American Journal of Therapeutics

Volumn 22, Issue 3, 2015, Pages e84-e87

  Thajudeen, Bijin ^a   Madhrira, Machaiah ^a   Bracamonte, Erika ^a   Cranmer, Lee D ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA MEDICAL CENTER   (United States)

Author keywords

acute renal failure; granulomatous interstitial nephritis; ipilimumab

Indexed keywords

DACARBAZINE; IPILIMUMAB; PREDNISONE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DISEASE COURSE; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; GRANULOMATOUS INTERSTITIAL NEPHRITIS; HUMAN; HUMAN TISSUE; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY FUNCTION; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; STEROID THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMICALLY INDUCED; GRANULOMA;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; GRANULOMA; HUMANS; MALE; NEPHRITIS, INTERSTITIAL;

EID: 84929508057     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3182a32ddc     Document Type: Article

References (13)

1. Namagondlu G, Low SE, Seneviratne R,. Acute renal failure from nitrofurantoin-induced acute granulomatous interstitial nephritis. QJM. 2010; 103: 49-52.
2. Chmiel KD, Suan D, Liddle C,. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol. 2011; 29: e237-e240.
3. Beck KE, Blansfield JA, Tran KQ,. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-Associated antigen 4. J Clin Oncol. 2006; 24: 2283-2289.
4. Fadel F, El Karoui K, Knebelmann B,. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009; 361: 211.
5. Meehan SM, Josephson MA, Haas M,. Granulomatous tubulointerstitial nephritis in the renal allograft. Am J Kidney Dis. 2000; 36: E27.
6. Mignon F, Mery JP, Mougenot B,. Granulomatous interstitial nephritis. Adv Nephrol Necker Hosp. 1984; 13: 219-245.
7. Maker AV, Attia P, Rosenberg SA,. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol. 2005; 175: 7746-7754.
8. Berthod G, Lazor R, Letovanec I,. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol. 2012; 30.
9. Hodi FS, O'Day SJ, McDermott DF,. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
10. Juszczak A, Gupta A, Karavitaki N,. Ipilimumab-A novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol. 2012; 167: 1-5.
11. Preddie DC, Markowitz GS, Radhakrishnan J,. Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol. 2006; 1: 718-722.
12. Harmankaya K, Erasim C, Koelblinger C,. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol. 2011; 28: 1140-1144.
13. Fecher LA, Agarwala SS, Hodi F,. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013; 18: 733-743.